MigVax

Vaccine for Viruses in Humans

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in March 2020, MigVax operates with 1–10 employees. The company has raised $21.3M across four funding rounds from OurCrowd and Happiness Capital. In April 2020, MigVax secured an A Round of funding, with OurCrowd participating as a lead investor.

Business overview

MigVax is a Health Tech & Life Sciences company focused on developing vaccines for human viruses. The company's core technology is a sub-unit vaccine approach utilizing a chimeric protein to present viral proteins to the immune system. This method, based on a successful avian coronavirus vaccine, aims to generate mucosal, blood-based, and cell-mediated immunity. MigVax primarily operates in the Pharmaceuticals sector, specifically in Drugs Discovery & Development, with an initial focus on COVID-19.

Strategic signal

In June 2022, MigVax partnered with Catalent to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19. This collaboration signals a strategic move towards innovative drug delivery methods and potentially broader market accessibility for their vaccine technology, indicating a focus on advanced formulation and patient convenience in vaccine development.

Log in to access full profile

Company Intelligence Q&A

What was a significant recent partnership for MigVax?
In June 2022, MigVax signed an agreement with Catalent to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19. This partnership aims to advance the formulation and delivery of their vaccine candidate.
When did MigVax appoint its new CEO?
MigVax appointed Ran Amir as its new CEO in May 2022, signaling a leadership transition for the company.
Which investors participated in MigVax's April 2020 funding round?
In April 2020, MigVax received funding from OurCrowd, which was a lead investor, and Happiness Capital.
Has MigVax received any grants?
In November 2021, MigVax secured a grant from The Coalition of Epidemic Preparedness Innovations (CEPI) to fast-track development of its oral vaccine.
What was a key preclinical trial outcome for MigVax's vaccine?
In June 2021, preclinical trials for MigVax's subunit oral COVID-19 vaccine demonstrated its effectiveness as a booster.
Log in to access full profile